ZA200208710B - Novel process. - Google Patents

Novel process.

Info

Publication number
ZA200208710B
ZA200208710B ZA200208710A ZA200208710A ZA200208710B ZA 200208710 B ZA200208710 B ZA 200208710B ZA 200208710 A ZA200208710 A ZA 200208710A ZA 200208710 A ZA200208710 A ZA 200208710A ZA 200208710 B ZA200208710 B ZA 200208710B
Authority
ZA
South Africa
Prior art keywords
novel process
novel
stable
formoterol
copd
Prior art date
Application number
ZA200208710A
Other languages
English (en)
Inventor
Eva Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200208710(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200208710B publication Critical patent/ZA200208710B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Separation By Low-Temperature Treatments (AREA)
ZA200208710A 2000-05-19 2002-10-28 Novel process. ZA200208710B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0012261.4A GB0012261D0 (en) 2000-05-19 2000-05-19 Novel process

Publications (1)

Publication Number Publication Date
ZA200208710B true ZA200208710B (en) 2004-02-10

Family

ID=9892016

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208710A ZA200208710B (en) 2000-05-19 2002-10-28 Novel process.

Country Status (19)

Country Link
US (3) US7179489B2 (xx)
EP (1) EP1289505B1 (xx)
JP (3) JP5739597B2 (xx)
KR (1) KR100799452B1 (xx)
CN (1) CN1245962C (xx)
AT (1) ATE276748T1 (xx)
AU (2) AU5900601A (xx)
BR (1) BRPI0110947B8 (xx)
CA (1) CA2409660C (xx)
DE (1) DE60105807T2 (xx)
ES (1) ES2227190T3 (xx)
GB (1) GB0012261D0 (xx)
IL (2) IL152532A0 (xx)
MX (1) MXPA02011310A (xx)
NO (1) NO20025220D0 (xx)
NZ (1) NZ522419A (xx)
PT (1) PT1289505E (xx)
WO (1) WO2001089491A1 (xx)
ZA (1) ZA200208710B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EA007377B1 (ru) 2002-08-21 2006-10-27 Нортон Хелткэа Лтд. Композиции для ингаляции
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
JP4755495B2 (ja) 2002-12-12 2011-08-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 組合せ医薬品
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
PT1651270E (pt) * 2003-07-29 2007-04-30 Boehringer Ingelheim Int Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico
EP1670482B2 (en) 2003-09-16 2022-06-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2005123072A1 (en) * 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
WO2006086270A1 (en) 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア, インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010144043A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab A novel 4-methylbenzenesulphonate salt and a process for preparing a pharmaceutical composition comprising the salt
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
DK2538922T3 (en) * 2010-02-25 2016-07-04 Andi-Ventis Ltd The formulation of compositions for the treatment of inflammatory conditions
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013109208A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations comprising formoterol as active agent
EP2804583A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
SG10201703243QA (en) * 2012-02-28 2017-06-29 Iceutica Holdings Inc Inhalable pharmaceutical compositions
EP4034079A1 (en) 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Novel carrier particles for dry powder formulations for inhalation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
EP0525388B1 (de) * 1991-07-01 1995-09-20 Gerhard Dr. Gergely Lutsch- oder Kautablette
JPH0558911A (ja) * 1991-08-27 1993-03-09 N D Shinyaku Kaihatsu Kenkyusho:Kk 鎮咳去痰剤
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
SK284889B6 (sk) 1998-11-13 2006-02-02 Jago Research Ag Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu
US6034604A (en) * 1999-01-14 2000-03-07 Kaltner; George Deactivation prevention for electronic article surveillance systems
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
US20030129245A1 (en) 2003-07-10
US20070259048A1 (en) 2007-11-08
CA2409660A1 (en) 2001-11-29
IL219785A (en) 2015-10-29
KR20030001514A (ko) 2003-01-06
US7670625B2 (en) 2010-03-02
MXPA02011310A (es) 2003-04-25
AU5900601A (en) 2001-12-03
BR0110947A (pt) 2003-04-29
GB0012261D0 (en) 2000-07-12
JP2003534272A (ja) 2003-11-18
ES2227190T3 (es) 2005-04-01
AU2001259006B2 (en) 2005-03-24
JP2013040214A (ja) 2013-02-28
NO20025220L (no) 2002-10-31
KR100799452B1 (ko) 2008-01-30
ATE276748T1 (de) 2004-10-15
EP1289505A1 (en) 2003-03-12
IL152532A0 (en) 2003-06-24
WO2001089491A1 (en) 2001-11-29
PT1289505E (pt) 2005-01-31
BRPI0110947B1 (pt) 2016-12-27
DE60105807T2 (de) 2005-11-24
US20100183729A1 (en) 2010-07-22
EP1289505B1 (en) 2004-09-22
NZ522419A (en) 2003-08-29
JP2015042693A (ja) 2015-03-05
JP5739597B2 (ja) 2015-06-24
CN1245962C (zh) 2006-03-22
CA2409660C (en) 2011-02-08
DE60105807D1 (de) 2004-10-28
BRPI0110947B8 (pt) 2021-05-25
IL219785A0 (en) 2012-06-28
US7179489B2 (en) 2007-02-20
NO20025220D0 (no) 2002-10-31
CN1429103A (zh) 2003-07-09

Similar Documents

Publication Publication Date Title
AU5900601A (en) Novel process
IL152470A0 (en) Pharmaceutical composition comprising micronised formoterol and micronised glucocorticosteroid
BE2013C023I2 (xx)
AP2002002590A0 (en) Pyrimidinyl carboxamides useful as inhibitors of PDE4 isozymes.
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
CA2395653A1 (en) New inhalable powder containing tiotropium
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
SE9900833D0 (sv) Novel combination
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
SE9900834D0 (sv) Novel combination
MXPA04007294A (es) Composicion para inhalacion.
WO2003075826A3 (en) Process for manufacturing pharmaceutical composition comprises of mycobacterium w in the treatment of asthma(obstructive lung disease)